Phase 2 trials in New Zealand 12 and Indonesia 9 have shown RV3.BB to be safe, to be as effective as currently deployed vaccines, and to be at least as effective when given from birth as when given from 6 weeks. Surveillance after natural neonatal RV3 infection suggests that one birth dose could be enough. 7 If it is shown to be adequately protective, easier access to children and lower costs of vaccine production and distribution will improve vaccination coverage-and the fear of intussusception will be lessened.
The challenge is to find a mechanism through which to do an ethically appropriate clinical trial of one dose given at birth, of the RV3.BB vaccine and any other suitable candidate vaccines. 
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